Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.73 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | SCN4A | P35499 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18579714 | 1.00 | TACR1 (0.73) | TACR1EPHX1TSHRANPEPSCN4A | |
| SCHEMBL18579716 | 1.00 | TACR1 (0.73) | TACR1EPHX1TSHRANPEPSCN4A | |
| Hydrochloric Acid SCHEMBL6735402 | 0.98 | TACR1 (0.71) | TACR1EPHX1TSHRANPEPSCN4A | |
| Hydrochloric Acid SCHEMBL901442 | 0.98 | TACR1 (0.71) | TACR1EPHX1TSHRANPEPSCN4A | |
| Hydrochloric Acid SCHEMBL6898377 | 0.98 | TACR1 (0.71) | TACR1EPHX1TSHRANPEPSCN4A | |
| SCHEMBL18394417 | 0.90 | TACR1 (0.63) | TACR1EPHX1TSHRCA1CA2 | |
| SCHEMBL903565 | 0.86 | TACR1 (0.57) | TACR1EPHX1ANPEPCA1SLC1A1 | |
| SCHEMBL7967707 | 0.86 | TACR1 (0.59) | TACR1EPHX1TSHRCA1CA2 | |
| SCHEMBL7965700 | 0.86 | TACR1 (0.59) | TACR1EPHX1TSHRCA1CA2 | |
| SCHEMBL2781643 | 0.86 | TACR1 (0.59) | TACR1EPHX1TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| CN-108368083-B | Heteroaryl compounds and their use as therapeutic agents | 东亚首希控股股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2019-04-25 | — | — | US | disclosed |
| CN-103826661-B | Novel binding agent-drug conjugates (ADCs) and uses thereof | 西雅图基因公司 | 2019-03-05 | — | — | CN | disclosed |
| US-10125118-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-11-13 | — | — | US | disclosed |
| CN-108368083-A | heteroaryl compounds and their use as therapeutic agents | 东亚首希控股股份有限公司 | 2018-08-03 | — | — | CN | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143499-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143495-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012041805-A1 | N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-RE39088-E1 | Amide compounds and use of the same | JAPAN TOBACCO, INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-0849256-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | JAPAN TOBACCO INC (JP) | 2005-06-08 | — | — | EP | disclosed |
| EP-1304322-A2 | Carboxylic acid compound and use thereof | Japan Tobacco Inc. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6420561-B1 | Amide compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6174887-B1 | Amide compounds and use of the same | JAPAN TOBACCO INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0849256-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Japan Tobacco Inc. (JP) | 1998-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | TACR1 801/4885EPHX1 2799/4885TSHR 1878/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | TACR1 801/4885EPHX1 2799/4885TSHR 1878/4885 |
| US-10125118-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | TACR1 801/4885EPHX1 2799/4885TSHR 1878/4885 |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | TACR1 801/4885EPHX1 2799/4885TSHR 1878/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | TACR1 801/4885EPHX1 2799/4885TSHR 1878/4885 |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | TACR1 906/4885EPHX1 3877/4885TSHR 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.